Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company focused on developing targeted genetic medicine therapies, is set to host an investor webinar on July 24, 2025, at 4:15 p.m. ET. The webinar, led by CEO Eric Poma, Ph.D., will focus on the company's RedTail(TM) platform, a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. This event is significant as it will provide insights into the company's progress toward an Investigational New Drug (IND) filing and its efforts to secure strategic pharmaceutical partnerships for commercialization.
The RedTail platform represents a promising advancement in the field of immuno-oncology, with preclinical data on lead candidate CLD-401 demonstrating tumor elimination and the activation of immune memory. These findings are crucial as they suggest the potential for long-term cancer remission and prevention of metastatic disease, addressing a significant unmet need in cancer treatment. The webinar will also include a Q&A session, offering investors and the broader public an opportunity to engage with the company's leadership on these developments.
For those interested in learning more about Calidi Biotherapeutics and its innovative approaches to cancer treatment, additional information can be found at https://www.calidibio.com. The upcoming webinar underscores the importance of Calidi's work in advancing oncology treatments and its potential impact on patients worldwide, marking a significant step forward in the fight against cancer.
